Drug intelligence / Profile preview

WO-3992

Development stage: Unknown
Lead developer: Dr August Wolff
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

WO-3992 is a topical agent developed by Dr. August Wolff & KG Arzneimittel for the treatment of primary axillary hyperhidrosis, a condition characterized by excessive underarm sweating. The drug is designed for topical administration and is currently investigational. Its mechanism of action is described as a retro metabolically designed anticholinergic agent that selectively binds to the Muscarinic acetylcholine receptor M3, potentially inhibiting sweat production. As of now, WO-3992 has not received regulatory approval in any country.

Other names: wo-3992wo3992wo 3992

Targets

CHRM3 (M3)

Beyond the preview

Go deeper on WO-3992.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WO-3992.

Explore the full profile